Reported Earnings • Aug 29
Full year 2026 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2025) Full year 2026 results: AU$0.001 loss per share (improved from AU$0.004 loss in FY 2025). Revenue: AU$21.4m (up 11% from FY 2025). Net loss: AU$1.91m (loss narrowed 67% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance. Announcement • Jul 27
ECS Botanics Holdings Ltd Expands OzSun Portfolio With All-In-One Vape Range ECS Botanics Holdings Ltd. announced the planned launch of two 2g all-in-one rosin blend inhalation products under its OzSun brand in mid-August 2026. The range will expand ECS’s higher-margin branded B2C portfolio into a larger-format, integrated vape product and will be supplied by Canadian GMP-licensed medicinal cannabis manufacturer Ichor Inc. under an executed consignment agreement. The initial products have been manufactured and are undergoing final packaging ahead of shipment to Australia. The required Australian import approvals have been obtained, with the planned launch subject to completion of packaging, importation and customary release-for-supply procedures. The initial range will comprise two tri-blend formulations aligned with the existing OzSun Day and Night product architecture. Each formulation combines three cannabinoids, with CBG included in the Day formulation and CBN included in the Night formulation. The products use rosin blend formulations combining rosin and distillate, with native cannabis terpenes incorporated into the final formulation. The formulations have been developed without making specific therapeutic claims and will be supplied within Australia’s existing prescription medicinal cannabis framework. Each product contains 2g of formulation with the rosin and distillate blend manufactured in Canada, with native terpenes incorporated into the formulation. The all-in-one format combines the reservoir, battery, heating system and mouthpiece within a single inhalation-activated unit. The device is rechargeable through a USB-C port and uses a proprietary ceramic heating core. This removes the need for a separate battery device required by traditional 510-thread cartridges and provides a self-contained format that is ready for use following dispensing. At 2g, the OzSun products will provide twice the fill volume of the 1g format currently prevalent in the Australian medicinal cannabis vape category. The larger format is intended to provide competitive value per gram and differentiate OzSun within the existing product market. The products will be supplied under a consignment arrangement with Ichor, under which the majority of the product cost becomes payable as inventory is sold. The consignment structure provides ECS with a capital-efficient pathway to establish demand before scaling subsequent orders. Based on current proposed pricing and landed product costs, ECS expects the range to generate gross margins broadly consistent with the Company’s higher-margin AVANI branded products. Vape products have become an established category across mature North American cannabis markets. BDSA retail sales data for the 12 months to May 2026 indicates that vapes represented approximately 26% of total US legal cannabis retail sales and generated approximately USD 8,000 million in category revenue, increasing by 6% from the prior corresponding period. Within the category, disposable vape sales increased by 41%, with BDSA identifying the growth of larger-format 2g products as an important driver of value and category development. Although ECS has not used the North American data as a forecast of Australian demand, the Company considers the category’s development supportive of the strategic rationale for adding a larger-format, integrated vape product to the OzSun portfolio. The OzSun all-in-one range is scheduled to launch in mid-August 2026 through ECS’s existing Australian medicinal cannabis distribution channels, supported by the Company’s Medical Science Liaison engagement with healthcare professionals. ECS will monitor initial sales and product uptake before determining the timing and scale of subsequent orders. The Company expects the new range to support continued growth and diversification of its branded B2C portfolio. Further updates will be provided where sales performance, additional product launches or expansion of the range become material. 
